Clinical Drug Development

The onset of COVID was a pivot for research companies to move towards a connected and patient-driven technology-oriented model of operations in clinical drug development. Coupled with the advent of mHealth technologies, IoMT led a revolution in study conduct with telemedicine, e-consent, eCOA and direct-to-patient shipments going mainstream.

NTT DATA, with its heritage of multi-million-dollar investments in life sciences innovation, has long been a protagonist to reform clinical study conduct. We have developed IP to expedite study conduct timelines with data-driven operations. Our engagement on real-world data, systems interoperability and employing AI ML, IoT and allied suite has driven positive results, bringing faster and predictive clinical outcomes for our clients.